藥品參考
Ciltacabtagene autoleucel
Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for multiple myeloma.
- 藥物類別: Miscellaneous
- 用途: multiple myeloma
最後更新 來源: US FDA label
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Miscellaneous
- ATC 代碼
- L01XL05
- 已知交互作用
- 68 (嚴重: 46 · 中度: 21 · 輕微: 1)
- 商品名
- 1
- 國家與市場
- 1
用途
作用方式
BCMA-directed, genetically modified autologous T cell immunotherapy. The CAR has two BCMA-targeting single-domain antibodies, a 4-1BB co-stimulatory domain and a CD3-zeta signaling domain. On binding BCMA-expressing cells, the CAR promotes T cell activation, expansion and elimination of target cells.
成人常用劑量（仿單摘要）
Relapsed or refractory multiple myeloma: single IV infusion of 0.5–1.0×10^6 CAR-positive viable T cells per kg body weight; maximum 1×10^8 CAR-positive viable T cells per single infusion
懷孕與哺乳
- 懷孕
- Unsafe No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment.
- 哺乳
- Unknown No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.
已通報的副作用
- Pyrexia
- Cytokine release syndrome
- Hypogammaglobulinemia
- Hypotension
- Musculoskeletal pain
- Fatigue
黑框警語
- Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids. Fatal or life-threatening ICANS, parkinsonism and Guillain-Barré syndrome occurred; monitor for neurologic events. HLH/MAS, prolonged and recurrent cytopenias, immune effector cell-associated enterocolitis, and secondary hematological malignancies (MDS, AML, T-cell malignancies) have occurred.
哪些人需要特別留意
- Increased early mortality in CARTITUDE-4: 14% of deaths in the CARVYKTI arm versus 12% in the control arm within 10 months
- Monitor at least daily for 7 days for CRS and neurologic toxicities; confirm that a minimum of two doses of tocilizumab are available before infusion
- Prolonged and recurrent cytopenias; monitor blood counts before and after infusion
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (68)
- Adalimumab + Ciltacabtagene autoleucel Major
- Anti-thymocyte + Ciltacabtagene autoleucel Major
- Azathioprine + Ciltacabtagene autoleucel Major
- Baricitinib + Ciltacabtagene autoleucel Major
- Basiliximab + Ciltacabtagene autoleucel Major
- Bendamustine + Ciltacabtagene autoleucel Major
- Capecitabine + Ciltacabtagene autoleucel Major
- Carboplatin + Ciltacabtagene autoleucel Major
- Certolizumab pegol + Ciltacabtagene autoleucel Major
- Chlorambucil + Ciltacabtagene autoleucel Major
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Ciltacabtagene autoleucel 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
在網頁版免費試用 Pro+ 14 天，無需信用卡。
常見問題
What is Ciltacabtagene autoleucel used for?
Ciltacabtagene autoleucel is a medicine in the class miscellaneous. It is used for Multiple myeloma.
What side effects have been reported with Ciltacabtagene autoleucel?
Pyrexia, Cytokine release syndrome, Hypogammaglobulinemia, Hypotension, Musculoskeletal pain, Fatigue. Serious warning: Fatal or life-threatening CRS occurred; do not give to patients with active infection or inflammatory disorders; treat severe CRS with tocilizumab or tocilizumab and corticosteroids.
Can Ciltacabtagene autoleucel be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No data in pregnancy. CAR-T cells may cross the placenta and cause fetal B-cell depletion and low antibody levels. Not recommended in pregnancy or without contraception; confirm a negative pregnancy test before treatment. Breastfeeding: Unknown. No information on presence in milk or effects on the infant. Weigh breastfeeding benefits against the mother's need; follow the guidance for the lymphodepleting chemotherapy.
What does Ciltacabtagene autoleucel interact with?
MediHelp lists 68 known interactions for Ciltacabtagene autoleucel. Major: 46 · Moderate: 21 · Minor: 1. The most serious include Adalimumab, Anti-thymocyte, Azathioprine.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
